Related Experiment Video
Updated: Jun 13, 2026
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
ST2: a novel biomarker for heart failure
Anju Bhardwaj1, James L Januzzi
1Cardiology Division, Massachusetts General Hospital, 32 Fruit Street, Yawkey 5984, Boston, MA 02114, USA.
Expert Review of Molecular Diagnostics
|May 15, 2010
Summary
Soluble ST2 (sST2) is a novel cardiovascular biomarker indicating ventricular biomechanical overload and heart failure severity. Elevated sST2 levels are valuable for predicting heart failure prognosis.
Area of Science:
- Cardiovascular Medicine
- Biomarker Discovery
- Immunology
Background:
- ST2 is an IL-1 receptor family member with transmembrane (ST2L) and soluble (sST2) isoforms.
- Initially linked to inflammatory diseases, ST2/IL-33 signaling is now recognized for its role in cardiac remodeling.
- Soluble ST2 (sST2) has emerged as a key biomarker in cardiovascular medicine.
Purpose of the Study:
- To review the prognostic utility of sST2 in heart failure.
- To discuss the role of sST2 as a biomarker for ventricular biomechanical overload.
- To explore current and future applications of sST2 in cardiovascular prognostication.
Main Methods:
- Literature review of studies investigating sST2 in heart failure.
- Analysis of the relationship between sST2 concentrations and heart failure severity.
- Evaluation of sST2's prognostic value in various heart failure cohorts.
Main Results:
- sST2 concentrations correlate with the presence and severity of heart failure.
- Elevated sST2 levels are significantly associated with adverse cardiovascular outcomes.
- sST2 provides incremental prognostic information beyond traditional heart failure biomarkers.
Conclusions:
- sST2 is a valuable prognostic biomarker in heart failure.
- The ST2/IL-33 pathway plays a critical role in cardiac remodeling and biomechanical stress.
- Further research is warranted to optimize the clinical application of sST2 in heart failure management.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...